Cargando…

Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF‐TIMI 48 Trial

BACKGROUND: Digoxin is widely used in patients with atrial fibrillation despite the lack of randomized controlled trials. Observational studies report conflicting results regarding its association with mortality, perhaps because of residual confounding by the presence of heart failure (HF). METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eisen, Alon, Ruff, Christian T., Braunwald, Eugene, Hamershock, Rose A., Lewis, Basil S., Hassager, Christian, Chao, Tze‐Fan, Le Heuzey, Jean Yves, Mercuri, Michele, Rutman, Howard, Antman, Elliott M., Giugliano, Robert P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586309/ https://www.ncbi.nlm.nih.gov/pubmed/28666993 http://dx.doi.org/10.1161/JAHA.117.006035

Ejemplares similares

Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF‐TIMI 48 Trial
por: Eisen, Alon, et al.
Publicado: (2016)

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial
por: Xu, Haiyan, et al.
Publicado: (2016)

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial
por: Kato, Eri Toda, et al.
Publicado: (2016)

Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial
por: Fanola, Christina L., et al.
Publicado: (2018)

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial
por: Zelniker, Thomas A., et al.
Publicado: (2021)

Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial
por: Wang, Kaijun, et al.
Publicado: (2017)

Dynamic TIMI Risk Score for STEMI
por: Amin, Sameer T., et al.
Publicado: (2013)

Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial
por: Wilkinson, Chris, et al.
Publicado: (2020)

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
por: Murphy, Sabina A., et al.
Publicado: (2008)

ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation
por: ElMaghawry, Mohamed
Publicado: (2015)

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
por: Bergmark, Brian A., et al.
Publicado: (2018)

Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post‐Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS‐TIMI 46 and ATLAS ACS 2‐TIMI 51
por: Gibson, William J., et al.
Publicado: (2019)

Predictors of Nonuse of a High‐Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib‐Thrombolysis in Myocardial Infarction 52 (SOLID‐TIMI 52) Trial
por: Eisen, Alon, et al.
Publicado: (2017)

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018)

Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
por: Bergmark, Brian A., et al.
Publicado: (2021)

Inappropriate use of digoxin in patients presenting with digoxin toxicity
por: Tatlisu, Mustafa Adem, et al.
Publicado: (2015)

SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins
por: Singh, Awadhesh K., et al.
Publicado: (2019)

Digoxin-induced retinal degeneration depends on rhodopsin
por: Landfried, Britta, et al.
Publicado: (2017)

Management and outcome across the spectrum of high‐risk patients with myocardial infarction according to the thrmobolysis in myocardial infarction (TIMI) risk‐score for secondary prevention
por: Grinberg, Tzlil, et al.
Publicado: (2021)

Use of digoxin-specific antibody fragments (Fab) in the management of digoxin poisoning.
por: Brown, J. H., et al.
Publicado: (1986)

Digoxin Therapy of Fetal Superior Ventricular Tachycardia: Are Digoxin Serum Levels Reliable?
por: Saad, Antonio F., et al.
Publicado: (2016)

Chronic Digoxin Toxicity: An Evaluation of Digoxin-Specific Antibodies and Other Management Options
por: Clifford, Liam M, et al.
Publicado: (2023)

Temporal trends in the pre-procedural TIMI flow grade among patients with ST- segment elevation myocardial infarction – From the ACSIS registry
por: Schamroth Pravda, Nili, et al.
Publicado: (2021)

TIMI perfusion grade compared to TIMI flow in prediction of infarct size and microvascular obstruction measured by contrast-enhanced MRI
por: Fuernau, Georg FK, et al.
Publicado: (2009)

Serum digoxin concentrations in dogs with atrial fibrillation under long term digoxin treatment
por: Colella, Antonella, et al.
Publicado: (2022)

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50
por: Kidd, Stephen K., et al.
Publicado: (2016)

Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54
por: Dellborg, Mikael, et al.
Publicado: (2019)

Efficacy and safety of digoxin in acute heart failure triggered by tachyarrhythmia
por: Shrestha, Samyut, et al.
Publicado: (2022)

Neglected facts in digoxin intoxication
por: Serin, Sibel Ocak
Publicado: (2017)

‘Digoxin conundrum – Time for validation?’
por: Yadava, O.P.
Publicado: (2021)

Importance of the TIMI frame count: implications for future trials
por: Appleby, Mark A, et al.
Publicado: (2000)

Pharmacokinetic Considerations for Digoxin in Older People
por: Currie, Geoffrey M, et al.
Publicado: (2011)

Appropriateness of digoxin measurement in hospitalized patients
por: Oncu, Seyma, et al.
Publicado: (2017)

Immunosensor for Rapid and Sensitive Detection of Digoxin
por: Zhao, Shuyang, et al.
Publicado: (2023)

Implications of the PEGASUS-TIMI 54 trial for US clinical practice
por: Bradley, Steven M, et al.
Publicado: (2017)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies
por: Naccarelli, Gerald V., et al.
Publicado: (2020)

Comparison of Prediction Between TIMI (Thrombolysis in Myocardial Infarction) Risk Score and Modified TIMI Risk Score in Discharged Patients From Emergency Department With Atypical Chest Pain
por: Abbasnezhad, Mohsen, et al.
Publicado: (2014)

Efficiency of individual dosage of digoxin with calculated concentration
por: Zhao, Li, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tpm4bmlq697i9kgpgbo2vbn21j